These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 21344383)

  • 21. Novel antiosteoclastogenic activity of phloretin antagonizing RANKL-induced osteoclast differentiation of murine macrophages.
    Kim JL; Kang MK; Gong JH; Park SH; Han SY; Kang YH
    Mol Nutr Food Res; 2012 Aug; 56(8):1223-33. PubMed ID: 22700286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
    Michael H; Härkönen PL; Väänänen HK; Hentunen TA
    J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The inhibitory effect of vitamin K on RANKL-induced osteoclast differentiation and bone resorption.
    Wu WJ; Kim MS; Ahn BY
    Food Funct; 2015 Oct; 6(10):3351-8. PubMed ID: 26267519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitory effect of cantharidin on osteoclast differentiation and bone resorption.
    Kim MH; Shim KS; Kim SH
    Arch Pharm Res; 2010 Mar; 33(3):457-62. PubMed ID: 20361312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coenzyme q10 regulates osteoclast and osteoblast differentiation.
    Moon HJ; Ko WK; Jung MS; Kim JH; Lee WJ; Park KS; Heo JK; Bang JB; Kwon IK
    J Food Sci; 2013 May; 78(5):H785-891. PubMed ID: 23582186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of ITAM adaptor molecules and their receptors by inhibition of calcineurin-NFAT signalling during late stage osteoclast differentiation.
    Zawawi MS; Dharmapatni AA; Cantley MD; McHugh KP; Haynes DR; Crotti TN
    Biochem Biophys Res Commun; 2012 Oct; 427(2):404-9. PubMed ID: 23000414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of the calcitonin receptor in bone marrow cell cultures and in bone: a specific marker of the differentiated osteoclast that is regulated by calcitonin.
    Lee SK; Goldring SR; Lorenzo JA
    Endocrinology; 1995 Oct; 136(10):4572-81. PubMed ID: 7664679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
    Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
    Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel small molecule, NecroX-7, inhibits osteoclast differentiation by suppressing NF-κB activity and c-Fos expression.
    Kim HJ; Yoon KA; Lee MK; Kim SH; Lee IK; Kim SY
    Life Sci; 2012 Nov; 91(19-20):928-34. PubMed ID: 23000100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of liver X receptor (LXR) inhibits receptor activator of nuclear factor κB ligand (RANKL)-induced osteoclast differentiation in an LXRβ-dependent mechanism.
    Remen KM; Henning P; Lerner UH; Gustafsson JÅ; Andersson G
    J Biol Chem; 2011 Sep; 286(38):33084-94. PubMed ID: 21784849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
    Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
    Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteoclasts are not activated in middle ear cholesteatoma.
    Koizumi H; Suzuki H; Ikezaki S; Ohbuchi T; Hashida K; Sakai A
    J Bone Miner Metab; 2016 Mar; 34(2):193-200. PubMed ID: 25796629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary human bone marrow adipocytes support TNF-α-induced osteoclast differentiation and function through RANKL expression.
    Goto H; Hozumi A; Osaki M; Fukushima T; Sakamoto K; Yonekura A; Tomita M; Furukawa K; Shindo H; Baba H
    Cytokine; 2011 Dec; 56(3):662-8. PubMed ID: 21963155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
    He L; Lee J; Jang JH; Lee SH; Nan MH; Oh BC; Lee SG; Kim HH; Soung NK; Ahn JS; Kim BY
    Bone; 2012 Jun; 50(6):1207-13. PubMed ID: 22484180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Purslane suppresses osteoclast differentiation and bone resorbing activity via inhibition of Akt/GSK3β-c-Fos-NFATc1 signaling in vitro and prevents lipopolysaccharide-induced bone loss in vivo.
    Kim JY; Oh HM; Kwak SC; Cheon YH; Lee MS; Rho MC; Oh J
    Biol Pharm Bull; 2015; 38(1):66-74. PubMed ID: 25744460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lanthanum Chloride Attenuates Osteoclast Formation and Function Via the Downregulation of Rankl-Induced Nf-κb and Nfatc1 Activities.
    Jiang C; Shang J; Li Z; Qin A; Ouyang Z; Qu X; Li H; Tian B; Wang W; Wu C; Wang J; Dai M
    J Cell Physiol; 2016 Jan; 231(1):142-51. PubMed ID: 26060084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zoledronate inhibits receptor activator of nuclear factor kappa-B ligand-induced osteoclast differentiation via suppression of expression of nuclear factor of activated T-cell c1 and carbonic anhydrase 2.
    Nakagawa T; Ohta K; Kubozono K; Ishida Y; Naruse T; Takechi M; Kamata N
    Arch Oral Biol; 2015 Apr; 60(4):557-65. PubMed ID: 25601046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low dose of propranolol down-modulates bone resorption by inhibiting inflammation and osteoclast differentiation.
    Rodrigues WF; Madeira MF; da Silva TA; Clemente-Napimoga JT; Miguel CB; Dias-da-Silva VJ; Barbosa-Neto O; Lopes AH; Napimoga MH
    Br J Pharmacol; 2012 Apr; 165(7):2140-51. PubMed ID: 21950592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
    Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
    Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.